Tumor cells circulating in the blood are the germ cells of breast cancer metastases. They are very rare and have not been ...

Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we ...

As we know, 65% to 70% of all breast cancers are HR-positive HER2-negative and this is also the most common subtype of metastatic breast cancer. The current standard of care for frontline therapy of ...

This page includes links to articles highlighting the top breast cancer research published on Cancer Therapy Advisor in 2024.

Findings from the HELEN-006 trial suggest a potential shift in neoadjuvant treatment practices for patients with HER2-positive early breast cancer, specifically using nab-paclitaxel to reduce ...

每经AI快讯，海创药业12月30日晚间公告，近日，公司收到美国食品药品监督管理局（简称“FDA”)的临床研究继续进行通知书，公司自主研发的HP568片用于治疗雌激素受体（EstrogenReceptor, ER）阳性和人表皮生长因子受体2（Human ...